Open Access

EDITORIAL

Leonard G. Gomella
Canadian Journal of Urology, Vol.28, No.4, pp. 10733-10733, 2021
Abstract This article has no abstract. More >

View

16

Download

15

Open Access

LEGENDS IN UROLOGY

Lodewijk (Louis) Jans Denis
Canadian Journal of Urology, Vol.28, No.4, pp. 10734-10737, 2021
Abstract This article has no abstract. More >

View

16

Download

15

Open Access

ARTICLE

Margaret E. Long¹, Andrew M. Vitale², Sarah L. Mott³, Chad Tracy², Rohan Garje³, Yousef Zakharia³, James A. Brown²
Canadian Journal of Urology, Vol.28, No.4, pp. 10738-10742, 2021
Abstract Introduction: Androgen deprivation therapy (ADT) is often used in the treatment of prostate cancer. Specific factors affecting testosterone recovery after cessation of ADT have not been well-characterized in existing literature.
Materials and methods: We retrospectively reviewed patients at our institution who received ADT between 1999 and 2018. Patients with at least one course of ADT and subsequent testosterone level within 12 months of cessation of ADT were included. Patients received at least one of the following four agents: leuprolide, goserelin, triptorelin, and degarelix. Cox regression models were utilized to estimate the effect of patient and treatment characteristics… More >

View

17

Download

19

Open Access

COMMENTARY

Judd W. Moul
Canadian Journal of Urology, Vol.28, No.4, pp. 10743-10743, 2021
Abstract This article has no abstract. More >

View

15

Download

19

Open Access

ARTICLE

Shuang Li¹, Viacheslav Iremashvili², Simone L. Vernez¹, Kristina L. Penniston¹, R. Allan Jhagroo³, Sara L. Best¹, Sean P. Hedican¹, Stephen Y. Nakada¹
Canadian Journal of Urology, Vol.28, No.4, pp. 10744-10749, 2021
Abstract Introduction: The objective of this study is to explore the association between urinary stone composition and surgical recurrence.
Materials and methods: Patients who underwent kidney stone surgeries (between 2009-2017), were followed for > 1 year, and had ≥ 1 stone composition analyses were included in our analysis. Surgical stone recurrence (repeat surgery) was defined as the second surgery on the same kidney unit. Recurrence-free survival analysis was used.
Results: A total number of 1051 patients were included (52.7% men, average age 59.1 ± 15.1 years). Over 4.7 ± 2.5 years follow-up, 26.7% of patients required repeat surgery. Patients’… More >

View

16

Download

25

Open Access

ARTICLE

Albert S. Lee, Hans G. Pohl, H. Gil Rushton, Tanya D. Davis
Canadian Journal of Urology, Vol.28, No.4, pp. 10750-10755, 2021
Abstract Introduction: To examine the impact of COVID-19 pandemic on the presentation, management and outcome of testicular torsion at our institution.
Materials and methods: A retrospective review of a prospectively maintained testicular torsion database was performed. Patients ≤ 18 years of age evaluated in our emergency room between 3/11/2020 to 10/1/2020 (during-COVID-19) and the same period in 2018 and 2019 (pre-COVID-19) with US diagnosed and OR confirmed testicular torsion were included. Basic demographics, timing of presentation, referral rate, time to OR and orchiectomy rate were extracted and compared. P < 0.05 was considered statistically significant.
Results: A total of… More >

View

19

Download

22

Open Access

ARTICLE

Cory A. Taylor¹, Conrad M. Tobert^1,2,3, Richard J. Kahnoski², John E. Humphrey², Brian R. Lane^1,2
Canadian Journal of Urology, Vol.28, No.4, pp. 10756-10761, 2021
Abstract Introduction: American Urological Association (AUA) guidelines recommend intravesical chemotherapy to be given following transurethral resection of a bladder tumor. Prior studies have shown the benefit of mitomycin as well as gemcitabine. However, no study has compared the two agents.
Materials and methods: The study was designed as an open label 1:1:1 randomized controlled trial, comparing intravesical mitomycin, gemcitabine, and saline as a single intraoperative instillation immediately following transurethral resection of suspected bladder tumor. Primary endpoint was any grade ≥ 3 events according to NCI CTCAE Version 4.03, this captures any return trip to the operating room for… More >

View

22

Download

21

Open Access

ARTICLE

Doreen A. Ezeife¹, Brendon Josh Morganstein², Steven Yip¹, Malcolm Ryan², Jennifer H. Law², Amy Yimin Guan³, Lisa W. Le³, Aaron R. Hansen², Adrian Sacher², Georg A. Bjarnason⁴, Mark K. Doherty⁴, Natasha B. Leighl²
Canadian Journal of Urology, Vol.28, No.4, pp. 10762-10767, 2021
Abstract Introduction: Advances in novel treatment options may render renal cell cancer (RCC) patients susceptible to the financial toxicity (FT) of cancer treatment, and the factors associated with FT are unknown.
Materials and methods: Eligible patients were ≥ 18 years old and had a diagnosis of stage IV RCC for at least 3 months. Patients were recruited from Princess Margaret Cancer Centre and Sunnybrook Odette Cancer Centre (Toronto, Canada). FT was assessed using the validated Comprehensive Score for Financial Toxicity (COST) instrument, a 12-question survey scored from 0-44, with lower scores reflecting worse FT. Patient and treatment characteristics,… More >

View

19

Download

21

Open Access

ARTICLE

Brian J. Morris¹, Jim G. Matthews², Noel Pabalan³, Stephen Moreton⁴, John N. Krieger⁵
Canadian Journal of Urology, Vol.28, No.4, pp. 10768-10776, 2021
Abstract Introduction: The relationship between circumcision and prostate cancer has been controversial. A recently published meta-analysis contradicted previous meta-analyses of male circumcision and prostate cancer risk. Our aim was to conduct a de novo meta-analysis and critically evaluate this recent paper published by Van Howe.
Materials and methods: We retrieved data from each of the 12 source studies Van Howe used, then performed a random effects meta-analysis of those data. We critically examined the data and other information in Van Howe’s study.
Results: Using the same values as Van Howe, we confirmed his finding of a positive association of… More >

View

16

Download

27

Open Access

COMMENTARY

T. Ernesto Figueroa
Canadian Journal of Urology, Vol.28, No.4, pp. 10777-10777, 2021
Abstract This article has no abstract. More >

View

17

Download

24

Open Access

ARTICLE

Steven J. Lomax¹, Daniela A. Haehn¹, Eric Robinson¹, Rachel Pung Page², Edsel Bittencourt³, Mark F.B. Hurdle³, Steven P. Petrou¹
Canadian Journal of Urology, Vol.28, No.4, pp. 10778-10782, 2021
Abstract Introduction: To compare the accuracy of the transcutaneous ultrasound (US) in detecting the tibial nerve (TN) as opposed to digital palpation in the performance of posterior tibial nerve stimulation (PTNS).
Materials and methods: After Institutional Review Board (IRB) approval, 25 adults were enrolled to quantify the difference in position of the distal TN by the use of US as opposed to cutaneous palpation. The position of the TN was determined first by the palpation method and then by using a L12-4MHz high frequency Linear Array Transducer. The difference in position between the two methods was determined in… More >

View

20

Download

34

Open Access

ARTICLE

Da David Jiang^1,2, Nicholas H. Chakiryan^1,2, Kyle A. Gillis^1,2, Jason C. Hedges¹, John M. Barry¹
Canadian Journal of Urology, Vol.28, No.4, pp. 10783-10787, 2021
Abstract Introduction: To evaluate the educational value of transplant rotation in urology residency. In the United States, exposure to kidney transplantation during urology residency has declined significantly over the past few decades. At our institution, transplantation has been a core component of urology residency since its inception in 1959.
Materials and methods: A 15-question anonymous survey was developed. The first 8 questions queried demographics, and the last 7 were a set of questions with a Likert Scale response. The survey was electronically mailed to past and current urology residents who had completed the transplant rotation, dating back to 1972.
… More >

View

19

Download

23

Open Access

HOW I DO IT

Dean Elterman¹, Bruce Gao¹, Kevin C. Zorn², Naeem Bhojani², Bilal Chughtai³
Canadian Journal of Urology, Vol.28, No.4, pp. 10788-10793, 2021
Abstract Benignprostatichyperplasiaisacommonandprogressive diseaseaffectingagingmenwhichhasasignifcantimpact on quality of life. The second-generation Temporarily Implanted Nitinol Device (iTind) is an FDA approved temporaryprostaticurethraldevicewhichcanbedeployed using standard fexible cystoscopy without sedation or generalanesthesia.Thedeviceisleftin-situfor5to7days and is then entirely removed in the offce, using an open-ended silicone catheter. Prospective, randomized data indicate that iTind has favorable functional and sexual patient outcomes. Readers will familiarize themselves withiTind,signifcanthistoricalstudiesandthetechnique for deploying iTind using a fexible cystoscope in the offce setting. More >

View

18

Download

20

Open Access

HOW I DO IT

Amit S. Bhattu¹, Chad R. Ritch^1,2, Mona Jahromi¹, Indraneel Banerjee¹, Mark L. Gonzalgo^1,2
Canadian Journal of Urology, Vol.28, No.4, pp. 10794-10798, 2021
Abstract Robotic radical cystectomy with urinary diversion has become increasingly utilized for the surgical management of bladder cancer. Orthotopic neobladder reconstruction is still performed worldwide primarily via an extracorporeal approach because of the difficulty associated with robotic intracorporeal reconstruction. The objective of this article is to demonstrate a stepwise approach for robotic intracorporeal neobladder in a standardized manner that adheres to the principles of open surgery. More >

View

20

Download

23

Open Access

RESIDENT’S CORNER

Kostantinos E. Morris^*, Dominic Grimberg^*, Rohith Arcot, Judd W. Moul
Canadian Journal of Urology, Vol.28, No.4, pp. 10799-10801, 2021
Abstract Prostatitis is a common cause of prostate-specific antigen (PSA) elevation but can masquerade underlying prostate cancer. We present a case of a man with undiagnosed prostate cancer whose initial PSA elevation of > 999.0 ng/mL was initially ascribed entirely to prostatitis. In the setting of possible prostatitis clinicians should avoid the knee jerk reaction to blame the totality of PSA elevation on prostatitis. A greatly elevated PSA may be a sign of an underlying prostate cancer and should be explored in the proper clinical setting. More >

View

21

Download

21